

Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

3rd August, 2021

Corporate Relationship Department M/s. BSE Ltd. Dalal Street, Fort <u>Mumbai 400 001.</u> Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Please find enclose herewith the Press Release for your information.

Thanking you,

Yours faithfully, For NATCO Pharma Limited

Marayano

M. Adinarayana Company Secretary & V.P.(Legal and Corp. Affairs)

Encl: a.a.



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/11/2021-22

Press release

NATCO transfers Lenalidomide ANDA to Arrow

Hyderabad, India, 3rd August, 2021

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces that it has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, 10mg, 15mg, 20mg and 25mg strengths) to Arrow International Limited as per an earlier agreement between the parties.

This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties.

Arrow International Limited (an affiliate of Teva Pharmaceutical Industries Ltd) is the marketing partner of NATCO for this product in the US market. The ANDA was approved by USFDA in May 2021 with final approval in the 5mg, 10mg, 15mg, and 25mg strengths, and tentative approval in the 2.5mg and 20mg strengths.

Forwarded for favor of publication For NATCO Pharma Limited

MAnarayano

M Adinarayana Company Secretary & Vice President (Legal & Corp. Affairs)